image credit: Adobe Stock

Pfizer told by FDA to test additional Paxlovid course in patients with COVID-19 rebound

August 22, 2022


The company must produce the initial results of a randomised controlled trial of a second course of the antiviral by 30 September next year, according to a letter from the regulator.

The order follows reports of rebounding COVID-19 symptoms after the first course of treatment, which Pfizer said were rare.

The FDA said a protocol for the study is expected to be finalised this month.

Read More on PMLiVE